Cellular and pharmacological selectivity of the peroxisome proliferator-activated receptor-β/δ antagonist GSK3787

Molecular Pharmacology

Volumn 78, Issue 3, 2010, Pages 419-430

  Palkar, Prajakta S ^a   Borland, Michael G ^a   Naruhn, Simone ^b   Ferry, Christina H ^a   Lee, Christina ^a   Sk, Ugir H ^c   Sharma, Arun K ^c   Amin, Shantu ^c   Murray, Iain A ^a   Anderson, Cherie R ^a   Perdew, Gary H ^a   Gonzalez, Frank J ^d   Müller, Rolf ^b   Peters, Jeffrey M ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c PENN STATE CANCER INSTITUTE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [2 [3 CYCLOHEXYL 1 (4 CYCLOHEXYLBUTYL)UREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; 3 [[[2 METHOXY 4 (PHENYLAMINO)PHENYL]AMINO]SULFONYL] 2 THIOPHENECARBOXYLIC ACID METHYL ESTER; 4 CHLORO N [2 [[(5 TRIFLUOROMETHYL) 2 PYRIDYL]SULFONYL]ETHYL]BENZAMIDE; ADIPOPHILIN; CELL PROTEIN; GSK 0660; GSK 3787; MESSENGER RNA; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PROTEIN ANGPTL4; ROSIGLITAZONE; UNCLASSIFIED DRUG; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; THIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FIBROBLAST; FLUORESCENCE RESONANCE ENERGY TRANSFER; GLUCOSE TOLERANCE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; MALE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; ANIMAL; CELL LINE; CELLS; CYTOLOGY; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; METABOLISM; TRANSCRIPTION INITIATION;

ANIMALS; CELL LINE; CELL PROLIFERATION; CELLS; HUMANS; KERATINOCYTES; MICE; MICE, KNOCKOUT; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PPAR ALPHA; PPAR GAMMA; PPAR-BETA; THIAZOLES; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 77956243463     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.065508     Document Type: Article

References (37)

1. Barak Y, Liao D, He W, Ong ES, Nelson MC, Olefsky JM, Boland R, and Evans RM (2002) Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci USA 99:303-308.
2. Berglund L, Björling E, Oksvold P, Fagerberg L, Asplund A, Szigyarto CA, Persson A, Ottosson J, Wernérus H, Nilsson P, et al. (2008) A genecentric Human Protein Atlas for expression profiles based on antibodies. Mol Cell Proteomics 7:2019-2027.
3. Billin AN (2008) PPAR-β/δ agonists for type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home. Expert Opin Investig Drugs 17:1465-1471.
4. Burdick AD, Kim DJ, Peraza MA, Gonzalez FJ, and Peters JM (2006) The role of peroxisome proliferator-activated receptor-β/δ in epithelial cell growth and differentiation. Cell Signal 18:9-20.
5. Chawla A, Lee CH, Barak Y, He W, Rosenfeld J, Liao D, Han J, Kang H, and Evans RM (2003) PPARδ is a very low-density lipoprotein sensor in macrophages. Proc Natl Acad Sci USA 100:1268-1273.
6. Dlugosz AA, Glick AB, Tennenbaum T, Weinberg WC, and Yuspa SH (1995) Isolation and utilization of epidermal keratinocytes for oncogene research. Methods Enzymol 254:3-20.
7. 2 to activate PPARβ. FEBS J 273:170-179.
8. Foreman JE, Sharma AK, Amin S, Gonzalez FJ, and Peters JM (2010) Ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) inhibits cell growth in a mouse mammary gland cancer cell line. Cancer Lett 288:219-225.
9. Foreman JE, Sorg JM, McGinnis KS, Rigas B, Williams JL, Clapper ML, Gonzalez FJ, and Peters JM (2009) Regulation of peroxisome proliferator- activated receptor-β/δ by the APC/β-CATENIN pathway and nonsteroidal antiinflammatory drugs. Mol Carcinog 48:942-952.
10. Gehrke S, Jérôme V, and Müller R (2003) Chimeric transcriptional control units for improved liver-specific transgene expression. Gene 322:137-143.
11. Girroir EE, Hollingshead HE, Billin AN, Willson TM, Robertson GP, Sharma AK, Amin S, Gonzalez FJ, and Peters JM (2008a) Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines. Toxicology 243:236-243.
12. Girroir EE, Hollingshead HE, He P, Zhu B, Perdew GH, and Peters JM (2008b) Quantitative expression patterns of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) protein in mice. Biochem Biophys Res Commun 371:456-461.
13. Gross B and Staels B (2007) PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. Best Pract Res Clin Endocrinol Metab 21:687-710.
14. He P, Borland MG, Zhu B, Sharma AK, Amin S, El-Bayoumy K, Gonzalez FJ, and Peters JM (2008) Effect of ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in human lung cancer cell lines. Toxicology 254:112-117.
15. Heinäniemi M, Uski JO, Degenhardt T, and Carlberg C (2007) Meta-analysis of primary target genes of peroxisome proliferator-activated receptors. Genome Biol 8:R147.
16. Hollingshead HE, Borland MG, Billin AN, Willson TM, Gonzalez FJ, and Peters JM (2008) Ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms. Carcinogenesis 29:169-176.
17. Hollingshead HE, Killins RL, Borland MG, Girroir EE, Billin AN, Willson TM, Sharma AK, Amin S, Gonzalez FJ, and Peters JM (2007) Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) ligands do not potentiate growth of human cancer cell lines. Carcinogenesis 28:2641-2649.
18. Jérôme V and Müller R (1998) Tissue-specific, cell cycle-regulated chimeric transcription factors for the targeting of gene expression to tumor cells. Hum Gene Ther 9:2653-2659.
19. Lee CH, Olson P, Hevener A, Mehl I, Chong LW, Olefsky JM, Gonzalez FJ, Ham J, Kang H, Peters JM, et al. (2006) PPARδ regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci USA 103:3444-3449.
20. Nadra K, Anghel SI, Joye E, Tan NS, Basu-Modak S, Trono D, Wahli W, and Desvergne B (2006) Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor β/δ. Mol Cell Biol 26:3266-3281.
21. Naruhn S, Meissner W, Adhikary T, Kaddatz K, Klein T, Watzer B, Müller-Brüsselbach S, and Müller R (2010) 15- Hydroxyeicosatetraenoic acid is a preferential peroxisome proliferator-activated receptor β/δ agonist. Mol Pharmacol 77:171-184.
22. Peters JM and Gonzalez FJ (2009) Sorting out the functional role(s) of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in cell proliferation and cancer. Biochim Biophys Acta 1796:230-241.
23. Peters JM, Hollingshead HE, and Gonzalez FJ (2008) Role of peroxisome-proliferator-activated receptor β/δ (PPARβ/δ) in gastrointestinal tract function and disease. Clin Sci 115:107-127.
24. Peters JM, Lee SS, Li W, Ward JM, Gavrilova O, Everett C, Reitman ML, Hudson LD, and Gonzalez FJ (2000) Growth, adipose, brain and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator- activated receptor β(δ). Mol Cell Biol 20:5119-5128.
25. Quinn CE, Hamilton PK, Lockhart CJ, and McVeigh GE (2008) Thiazolidinediones: effects on insulin resistance and the cardiovascular system. Br J Pharmacol 153:636-645.
26. Reilly SM and Lee CH (2008) PPARδ as a therapeutic target in metabolic disease. FEBS Lett 582:26-31.
27. Rockwell CE, Snider NT, Thompson JT, Vanden Heuvel JP, and Kaminski NE (2006) Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2. Mol Pharmacol 70:101-111.
28. Shearer BG and Hoekstra WJ (2003) Recent advances in peroxisome proliferator-activated receptor science. Curr Med Chem 10:267-280.
29. Shearer BG, Steger DJ, Way JM, Stanley TB, Lobe DC, Grillot DA, Iannone MA, Lazar MA, Willson TM, and Billin AN (2008) Identification and characterization of a selective peroxisome proliferator-activated receptor β/δ (NR1C2) antagonist. Mol Endocrinol 22:523-529.
30. Shearer BG, Wiethe RW, Ashe A, Billin AN, Way JM, Stanley TB, Wagner CD, Xu RX, Leesnitzer LM, Merrihew RV, et al. (2010) Identification and characterization of 4-chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl) benzamide (GSK3787), a selective and irreversible peroxisome proliferator-activated receptor delta (PPARdelta) antagonist. J Med Chem 53:1857-1861.
31. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, and Fruchart JC (1998) Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98:2088-2093.
32. Stafslien DK, Vedvik KL, De Rosier T, and Ozers MS (2007) Analysis of ligand-dependent recruitment of coactivator peptides to RXRβ in a time-resolved fluorescence resonance energy transfer assay. Mol Cell Endocrinol 264:82-89. (Pubitemid 46097305)
33. Sznaidman ML, Haffner CD, Maloney PR, Fivush A, Chao E, Goreham D, Sierra ML, LeGrumelec C, Xu HE, Montana VG, et al. (2003) Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ)-synthesis and biological activity. Bioorg Med Chem Lett 13:1517-1521.
34. Uh M, Björling E, Agaton C, Szigyarto CA, Amini B, Andersen E, Andersson AC, Angelidou P, Asplund A, Asplund C, et al. (2005) A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics 4:1920-1932.
35. Zaveri NT, Sato BG, Jiang F, Calaoagan J, Laderoute KR, and Murphy BJ (2009) A novel peroxisome proliferator-activated receptor δ antagonist, SR13904, has antiproliferative activity in human cancer cells. Cancer Biol Ther 8:1252-1261.
36. Zhang JH, Chung TD, and Oldenburg KR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4:67-73.
37. Zuo X, Peng Z, Moussalli MJ, Morris JS, Broaddus RR, Fischer SM, and Shureiqi I (2009) Targeted genetic disruption of peroxisome proliferator- activated receptor-δ and colonic tumorigenesis. J Natl Cancer Inst 101:762-767.